知情同意书

尊敬的患者朋友：

您好！我是杜若飞，是郑州大学护理与健康学院2019级护理学博士研究生，现正在设计课题“靶向治疗肺癌患者皮肤不良反应多学科团队干预研究”，此研究的目的是为了帮助您预防和管理皮肤不良反应，减少严重不良反应的发生，降低不良反应程度。医护人员根据您的皮肤不良反应制定合理的干预措施，帮助您和您同样经受皮肤不良反应困扰的病友缓解症状，提高生活质量。为确保您的权益不受损害，请您仔细阅读以下内容：

干预期间需要您按照时间安排完成课程和相应任务，进行沟通和反馈，每周1次，每次不超过2小时；问卷填写过程大概需要20~30min，如有不愿或不便回答的问题或不愿完成，您可以不回答或者选择退出本研究，您不会因此而受到不公平待遇；

调查是为了了解您的皮肤不良反应以及生活质量状况，不会对您的诊断和治疗带来影响，不会损害您的健康；本研究为医护人员制定更好的居家靶向治疗癌症患者皮肤不良反应管理措施提供了依据；您填写的资料我们将为您保密，在录入和分析资料时不会涉及您的姓名、身份等相关信息；本研究的结果可能发表在相关的学术期刊；如果您对本研究有任何疑问可以咨询本课题的负责人杜若飞（郑州大学：15236190153）；如您清楚上述内容并同意参与本课题研究，请您在下面签名处签上您的全名，您的签名只表示您已理解上述内容并同意参与本研究，不会对您今后的就医造成任何影响。

非常感谢您的参与！

我已阅读了以上内容，研究人员已向我解释了本课题的目的和意义，我知道我可以选择参加或随时退出。

我自愿参与本研究。

患者签名：张丽红

日期：2021年12月2日
Dear patients:

My name is Ruofei Du. I am a PhD candidate of the college of nursing and health of Zhengzhou University. I am designing a protocol of randomized controlled trial "Home-based multidisciplinary interventions on skin adverse reactions in EGFR-TKIs treated lung cancer patients". The purpose of this research is to help you prevent and manage skin adverse reactions, reduce the occurrence and degree of serious adverse reactions caused by EGFR-TKIs. The medical staff will formulate reasonable and effective intervention measures according to your skin adverse reactions to help you and other patients who are suffering from skin adverse reactions alleviate symptoms and improve the quality of life. To ensure that your rights and interests will be not damaged, please read the following carefully:

During the study period, you need to complete some courses and tasks according to the schedule, at the same time you should communicate with researchers and give feedback on more than 1 hour each time once a week. It will take you about 20~30min to fill the questionnaires. If you are unwilling or inconvenient to answer questions or are unwilling to complete, you can refuse to continue this study, and you will not be treated unfairly. The investigation is to understand your skin adverse reactions and quality of life, which will not affect your diagnosis and treatment, and will not damage your health. This study will provide a basis for medical staff to develop effective management measures for skin adverse reactions of cancer patients with EGFR-TKIs treatment at home. All your information will be kept confidential including your name, identity and other relevant information and will not be involved in the process of analyzing information. The results of this study may be published in relevant academic journals. If you have any questions about this research, you can consult Ruofei Du who are in charge of this study (Zhengzhou University, Tel:15236190153). If you understand the above content and agree to participate in this research, please sign your full name below. Your signature only means that you have understood the above content and agreed to participate in this research, which will not affect your future treatment. Thank you very much for your participation!

I have read the above content, and the researchers have explained the purpose and significance of this topic to me. I know I can participate or quit at any time. I volunteered to participate in this study.

Patient signature:

Date: